Skip to main content
43°
Rain
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ASLAN PHARMACEUTICALS LIMITED
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
March 27, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
March 12, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
March 11, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors
March 06, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat
February 29, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
January 08, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
January 02, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs
December 12, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference
November 20, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit
November 03, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
October 27, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
October 24, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
October 18, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress
October 13, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology Congress
September 22, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 07, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 11, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2b Study in Atopic Dermatitis
July 06, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD Trial Evaluating Eblasakimab in Atopic Dermatitis
July 05, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimab’s Unique Mechanism of Action in the Treatment of Atopic Dermatitis
June 23, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan
June 22, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
June 01, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Doses First Patient in Phase 2a Trial of Farudodstat in Alopecia Areata
May 18, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Presents New Data on Eblasakimab and Farudodstat in Two Late-Breaking Presentations at the 1st International Societies for Investigative Dermatology Meeting
May 15, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
April 28, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
TMO
ASLAN Pharmaceuticals Announces Four Abstracts on Eblasakimab and Farudodstat, Including Two Late-Breakers, to be Presented at the 1st International Societies for Investigative Dermatology Meeting
April 24, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
March 28, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 24, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
TMO
ASLAN Pharmaceuticals to Participate in Fireside Chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
March 22, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting
March 14, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Tickers
ASLN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.